Member Info for Scinv_temp

And by the way, orphan exclusivity is 6 years not 7-10.

Bermuda is sadly malevolent

Https://youtu.be/TkI4TuD5UEA?si=fWfSAXdvrJAmkkc3

Around 46min 30sec

LD: iscib1+ has to be a lot better

Illuminati, sorry master 🤣

Roses is the typical market fodder that sees the hand of the illuminaty behind every post that he doesn't like.

Https://youtu.be/TkI4TuD5UEA?si=fWfSAXdvrJAmkkc3

Around 46min 30sec

LD: iscib1+ has to be a lot better

🤣🤣🤣

The same thing applies as scancell, freedom to operate patents rather than securing exclusivity. The moment you try an enforce them, they are gone.

🤣🤣🤣

The ultimovacs patent is useless. You just don't get it.

And I did not say phase 2/3, I said biomarkers and then straight to randomised pivotal

Remember that neither the idea of using the variable regions of an antibody for epitopes, nor the epitopes themselves (in scib1 at least) EVER belonged to scancell anyway.

They will access that data from the regulators and scancell's publications. Are you seriously suggesting that scancell will somehow bury the data?

Iscib1+ having worldwide exclusivity means NOTHING, if the non avidimab scib1 works just as well with the same epitopes in the same population.

Anyway, to me this is not a planning exercise, I know this rather than speculating.

And by the way, orphan status in the US is infinitely better than not protection anywhere. You also seem to confuse market size with population size when in fact they are very different animals. EU market for therapeutics is very different from US.

It is sad that you think that those tricks would work. It really shows you understand very little about this space.

The major hurdle with the FDA is safety, with the FDA having higher tolerance when it comes to terminal diseases. With the phase 2 complete, that part is settled. They would go for a small biomarker equivalence followed by a randomised, if a serious contender decides to go ahead, they would have it marketed in 3 years.

Scancell trying to revive a dead patent without demonstrating clear superiority of iscib1+ vs scib1 in the same patient population isn't going to fool anyone that matters. Just you lot :)

BTW, if the combination patent extents exclusivity for both and it was filed after scib1 and iscib1+, how come iscib1+ has extended patent life? :)

And by the way, equivalence studies of biosimilars are typically shorter.

It's not necessarily that it won't be granted, it's more likely that the claims that will be granted won't really provide exclusivity to scancell, it is all about freedom to operate. You really don't know this space, yet you insist.

SCIB1 patents has expired but does have orphan status which gives it exclusivity for 6 years post marketing authorisation. Also, it includes epitopes that have been identified in hla a2 patients that have spontaneously recovered from melanoma (licensed non exclusively from NIH).

iSCIB1+ has additional epitopes that however don't have the credentials of scib1 so they are predicted rather than identified via reverse translation. The data on those epitopes are in scancells hands for some time now. The trial has been waiting for original scib1 to finish recruiting for some time now. Have you seen this data? Neither have I. That's because ... [insert your own opinion here].

So scancell decided to make one last desperate attempt to make iscib1+ work in non hla a2 patients.

Why not use iscib1+ in halal a2 patients? Because, without taking advantage of the orphan status, anyone can can just copy scib1 (which is not even scancell's invention) and just undercut them. That's the problem. And it's mostly a problem created by scancell themselves. Take SCIB1 which has value and guaranteed exclusivity (orphan status) to the finish line and fund glymab and modi.

Amateurs.

🤣🤣🤣

I advise you to stop calling yourself king of anything

What Bermuda said is not a point of view, it is the reality of what is happening. The new cohort is their ultimate attempt to make iscib1+ work well enough to move forward with. A mistake if you ask me. Get scib1 over the line, sell for $80-$100M and focus on glymabs and modi ffs.